Tandem Diabetes Care, Inc. (TNDM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Tandem Diabetes Care (TNDM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • 9 hours ago

Is it the Right Time to Hold TNDM Stock in Your Portfolio?

Tandem Diabetes is advancing next-generation insulin delivery technology and international expansion, but competition and supply constraints pose challenges to growth.

Zacks Investment Research • Oct 9, 2026

Tandem Diabetes Care to Announce Third Quarter 2026 Financial Results on November 5, 2026

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, plans to release its third quarter 2026 results after the financial markets close on Thursday, November 5, 2026. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its third quarter 2026 financial and operating results. A live webcast of the call will be available on Tandem Diab.

Business Wire • Oct 1, 2026

Tandem Mobi Automated Insulin Delivery System Now Available in Twelve International Markets

MILAN--(BUSINESS WIRE)---- $TNDM #T2D--The Tandem Mobi automated insulin delivery system with Control-IQ+ automated insulin delivery technology is now available in 12 international markets.

Business Wire • Sep 28, 2026

Tandem Diabetes Care (TNDM) Soars 7.7%: Is Further Upside Left in the Stock?

Tandem Diabetes Care (TNDM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Zacks Investment Research • Sep 17, 2026

Reasons to Retain Tandem Diabetes Stock in Your Portfolio Now

TNDM's expanding pump lineup and pay-as-you-go model support growth prospects, though macro and competitive pressures remain.

Zacks Investment Research • Sep 9, 2026

Innovative Insulin Pumps Drive Optimism for Tandem, Beta Bionics

On Friday, William Blair initiated coverage on Tandem Diabetes Care Inc. (NASDAQ:TNDM) and Beta Bionics Inc (NASDAQ:BBNX), noting that both companies are advancing initiatives to play in faster-growing segments of the insulin pump market.

Benzinga • Aug 21, 2026

Tandem Diabetes Care Maps Growth Plan With Pharmacy Shift and Tubeless Mobi

Tandem Diabetes Care NASDAQ: TNDM highlighted its plans to expand insulin pump adoption through a shift to pharmacy distribution in the U.S., direct sales in additional international markets and upcoming product launches, including a tubeless version of its Tandem Mobi pump.

MarketBeat • Aug 18, 2026

TNDM Q2 Loss Narrower Than Expected, Revenues Miss, Stock Up

Tandem Diabetes shares jump 19.1% after a narrower-than-expected Q2 loss, as higher pump shipments and a 57% gross margin offset a slight revenue miss.

Zacks Investment Research • Aug 12, 2026

Tandem Diabetes Care Q2 Earnings Call Highlights

Tandem Diabetes Care NASDAQ: TNDM reported second-quarter results that included record sales, pump shipments and gross margin for a second quarter, while management highlighted early progress in its transition to pharmacy-channel reimbursement and continued development of new insulin-delivery technologies.

MarketBeat • Aug 7, 2026